A Comprehensive Assessment of Lymphatic Filariasis in Sri Lanka Six Years after Cessation of Mass Drug Administration

PLoS Neglected Tropical Diseases

Volumn 8, Issue 11, 2014, Pages

  Rao, Ramakrishna U ^a   Nagodavithana, Kumara C ^b   Samarasekera, Sandhya D ^b   Wijegunawardana, Asha D ^b   Premakumara, Welmillage D Y ^b   Perera, Samudrika N ^b   Settinayake, Sunil ^b   Miller, J Phillip ^a   Weil, Gary J ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Sri Lanka Ministry of Health and Nutrition   (Sri Lanka)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; PARASITE ANTIBODY; ALBENDAZOLE; ANTHELMINTIC AGENT; ANTIFILARIAL AGENT; DIETHYLCARBAMAZINE; HELMINTH ANTIBODY; HELMINTH DNA; PARASITE ANTIGEN;

ADULT; ARTICLE; BLOOD SAMPLING; DISEASE SURVEILLANCE; DISEASE TRANSMISSION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENDER; HEALTH SURVEY; HUMAN; INFECTION CONTROL; LYMPHATIC FILARIASIS; MAJOR CLINICAL STUDY; MALE; MICROFILARIASIS; NONHUMAN; PATHOGEN CLEARANCE; POLYMERASE CHAIN REACTION; PREVALENCE; QUESTIONNAIRE; RISK FACTOR; SRI LANKA; ADOLESCENT; ANIMAL; BLOOD; CHILD; CROSS-SECTIONAL STUDY; CULEX; DISEASE CARRIER; DISEASE ERADICATION; ELEPHANTIASIS, FILARIAL; IMMUNOLOGY; ISOLATION AND PURIFICATION; LONGITUDINAL STUDY; MICROFILARIA; MIDDLE AGED; PARASITOLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; ALBENDAZOLE; ANIMALS; ANTHELMINTICS; ANTIBODIES, HELMINTH; ANTIGENS, HELMINTH; CHILD; CROSS-SECTIONAL STUDIES; CULEX; DIETHYLCARBAMAZINE; DISEASE ERADICATION; DNA, HELMINTH; ELEPHANTIASIS, FILARIAL; FEMALE; FILARICIDES; HUMANS; INSECT VECTORS; LONGITUDINAL STUDIES; MALE; MICROFILARIA; MIDDLE AGED; PREVALENCE; SRI LANKA; YOUNG ADULT;

EID: 84920381004     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0003281     Document Type: Article

References (29)

1. WHO (2013) Global programme to eliminate lymphatic filariasis: progress report for 2012. Wkly Epidemiol Rec 88: 389–399.
2. Abdulcader MH, Sasa M, (1966) Epidemiology and control of bancroftian filariasis in Ceylon. Jpn J Exp Med 36: 609–646.
3. Schweinfurth U, (1983) Filarial diseases in Ceylon: a geographic and historical analysis. Ecol Dis 2: 309–319.
4. Dissanaike AS, (1991) Filariasis in Ceylon then (1961) and in Sri Lanka now (1990–30 years on). Ann Trop Med Parasitol 85: 123–129.
5. AntifilariasisCampaign (2013) Annual reports. Ministry of Health, Sri Lanka Available at http://wwwfilariasiscampaignhealthgovlk/subpgs/03_reportshtml.
6. Horton J, Witt C, Ottesen EA, Lazdins JK, Addiss DG, et al. (2000) An analysis of the safety of the single dose, two drug regimens used in programmes to eliminate lymphatic filariasis. Parasitology 121 Suppl: S147–160.
7. WHO (2000) Preparing and implementing a national plan to eliminate lymphatic filariasis (in countries where onchocerciasis is not co-endemic). World Health Organization, Geneva, WHO/CDS/CPE/CEE/200016.
8. WHO (2011) Halfway towards eliminating lymphatic filariasis: Progress Report 2000–2009 and Strategic Plan 2010–2020 of the Global Programme to Eliminate Lymphatic Filariasis. WHO, 2011 (WHO/HTM/NTD/PCT/20106) Geneva: World Health Organization.
9. Gunawardena GS, Ismail MM, Bradley MH, Karunaweera ND, (2007) Impact of the 2004 mass drug administration for the control of lymphatic filariasis, in urban and rural areas of the Western province of Sri Lanka. Ann Trop Med Parasitol 101: 335–341.
10. Weerasooriya MV, Yahathugoda CT, Wickramasinghe D, Gunawardena KN, Dharmadasa RA, et al. (2007) Social mobilisation, drug coverage and compliance and adverse reactions in a Mass Drug Administration (MDA) Programme for the Elimination of Lymphatic Filariasis in Sri Lanka. Filaria J 6: 11.
11. Yahathugoda TC, Weerasooriya MV, Sunahara T, Kimura E, Samarawickrema WA, et al. (2014) Rapid assessment procedures to detect hidden endemic foci in areas not subjected to mass drug administration in Sri Lanka. Parasitol Int 63: 87–93.
12. Yahathugoda TC, Weerasooriya M, Samarawickrema WA, (2013) An independent evaluation of the programme for the elimination of lymphatic filariasis. Galle Medical Journal 18: 31–43.
13. WHO (2012) Expert Mission to Sri Lanka for verification of elimination of lymphatic filariasis. Report. World Health Organization (SEA-CD-245) New Delhi, India: 1–37.
14. Chu BK, Deming M, Biritwum NK, Bougma WR, Dorkenoo AM, et al. (2013) Transmission assessment surveys (TAS) to define endpoints for lymphatic filariasis mass drug administration: a multicenter evaluation. PLoS Negl Trop Dis 7: e2584.
15. WHO (2011) Monitoring and epidemiological assessment of mass drug administration in the Global Programme to Eliminate Lymphatic Filariasis: A manual for national elimination programmes. WHO, (WHO/HTM/NTD/PCT/2011 4) Geneva: World Health Organization.
16. Weil GJ, Ramzy RM, (2007) Diagnostic tools for filariasis elimination programs. Trends Parasitol 23: 78–82.
17. Irish SR, Moore SJ, Derua YA, Bruce J, Cameron MM, (2013) Evaluation of gravid traps for the collection of Culex quinquefasciatus, a vector of lymphatic filariasis in Tanzania. Trans R Soc Trop Med Hyg 107: 15–22.
18. Weil GJ, Lammie PJ, Weiss N, (1997) The ICT Filariasis Test: A rapid-format antigen test for diagnosis of bancroftian filariasis. Parasitol Today 13: 401–404.
19. Weil GJ, Curtis KC, Fischer PU, Won KY, Lammie PJ, et al. (2011) A multicenter evaluation of a new antibody test kit for lymphatic filariasis employing recombinant Brugia malayi antigen Bm-14. Acta Trop 120 Suppl 1: S19–22.
20. Rao RU, Atkinson LJ, Ramzy RM, Helmy H, Farid HA, et al. (2006) A real-time PCR-based assay for detection of Wuchereria bancrofti DNA in blood and mosquitoes. Am J Trop Med Hyg 74: 826–832.
21. Gass K, Beau de Rochars MV, Boakye D, Bradley M, Fischer PU, et al. (2012) A multicenter evaluation of diagnostic tools to define endpoints for programs to eliminate bancroftian filariasis. PLoS Negl Trop Dis 6: e1479.
22. Katholi CR, Toe L, Merriweather A, Unnasch TR, (1995) Determining the prevalence of Onchocerca volvulus infection in vector populations by polymerase chain reaction screening of pools of black flies. J Infect Dis 172: 1414–1417.
23. Katholi CR, Unnasch TR, (2006) Important experimental parameters for determining infection rates in arthropod vectors using pool screening approaches. Am J Trop Med Hyg 74: 779–785.
24. Ramzy RM, El Setouhy M, Helmy H, Ahmed ES, Abd Elaziz KM, et al. (2006) Effect of yearly mass drug administration with diethylcarbamazine and albendazole on bancroftian filariasis in Egypt: a comprehensive assessment. Lancet 367: 992–999.
25. Budge PJ, Dorkenoo AM, Sodahlon YK, Fasuyi OB, Mathieu E, (2014) Ongoing surveillance for lymphatic filariasis in Togo: assessment of alternatives and nationwide reassessment of transmission status. Am J Trop Med Hyg 90: 89–95.
26. WHO (2013) Lymphatic Filariasis: Practical Entomology. A Handbook for National Elimination Programmes. WHO Global Programme to Eliminate Lymphatic Filariasis: 1–90.
27. Eigege A, Kal A, Miri E, Sallau A, Umaru J, et al. (2013) Long-lasting insecticidal nets are synergistic with mass drug administration for interruption of lymphatic filariasis transmission in Nigeria. PLoS Negl Trop Dis 7: e2508.
28. Reimer LJ, Thomsen EK, Tisch DJ, Henry-Halldin CN, Zimmerman PA, et al. (2013) Insecticidal bed nets and filariasis transmission in Papua New Guinea. N Engl J Med 369: 745–753.
29. Stolk WA, de Vlas SJ, Habbema JD, (2006) Advances and challenges in predicting the impact of lymphatic filariasis elimination programmes by mathematical modelling. Filaria J 5: 5.